Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredOnceDaily |
yes
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
|
| gptkbp:ATCCode |
J05AX30
|
| gptkbp:brand |
gptkb:Hepcludex
|
| gptkbp:CASNumber |
1805781-93-8
|
| gptkbp:chemicalFormula |
C204H329N57O61
|
| gptkbp:developer |
MYR Pharmaceuticals
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:bulevirtide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hepcludex
|
| gptkbp:indication |
treatment of chronic hepatitis D in adults with compensated liver disease
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NTCP receptor blocker
entry inhibitor |
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache injection site reaction elevated bile acids |
| gptkbp:UNII |
6Z5B6D607F
|
| gptkbp:usedFor |
chronic hepatitis B
chronic hepatitis D |
| gptkbp:bfsParent |
gptkb:bulevirtide
gptkb:myrcludex_B |
| gptkbp:bfsLayer |
7
|